drugset / Trial / NCT02138786
Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, phase 2, single arm, open-label study of oral selinexor monotherapy in patients with Richter's Transformation, arising in the setting of prior chronic lymphocytic leukemia (CLL), after at least one chemo-immunotherapy regimen for CLL.
Timeline
- Start
- 2014-11-14
- Primary completion
- 2016-08-31
- Completion
- 2016-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 60 mg/m2 | Oral |
| Subject | Selinexor | Other / unclassified | 80 mg | Oral |